Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • Divisiones Nacionales
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Oficinas extranjeras
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Divisiones operativas
      • División de Aviación
      • División de Control de Desvíos
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Lo que hacemos
    • Orden público
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Educación y prevención
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Información sobre las drogas
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Carreras
    • Agentes especiales
      • Preguntas frecuentes de los agentes especiales
      • Anuncios de empleo para agentes especiales
    • Investigador de desvíos
      • Diversion Investigator Job Announcement
    • Especialista en investigación de inteligencia
      • Anuncios de trabajo de especialista en investigación de inteligencia
      • Preguntas frecuentes de los especialistas en investigación de inteligencia
      • Autoridad de contratación de la Categoría A: Especialista en investigación de inteligencia
    • Carreras de ciencias forenses
    • Carreras profesionales y administrativas
    • Carreras para estudiantes y de nivel básico
    • Cómo aplicar
      • Empleador con igualdad de oportunidades
      • Requisitos de empleo
      • Cómo reclamar la preferencia de los veteranos
      • Consideración prioritaria
      • Beneficios
      • Veteranos y personas con discapacidades
  • Recursos
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • Ley de Libertad de Información
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Buscar
  • Menú Completo

Main Menu

  • Quiénes somos
  • Lo que hacemos
  • Carreras
  • Recursos
  • Recibir Actualizaciones
  • Scam Alert
  • English
  • ES

PUBLIC SAFETY ALERT

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine - DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

Drug Enforcement Administration

David S. Olesky, Acting Special Agent in Charge
Rocky Mountain
@DEAROCKYMTNDiv
Octubre 18, 2018
Contact: Public Information Officer
Phone Number: 571-265-1238
For Immediate Release

Two South Denver pharmacists plead guilty to felony charges of illegally distributing opioids

DENVER – Stanley (Stan) G. Callas, age 66, of Parker, and Scott Alan Eskanos, age 63, of Highlands Ranch, pled guilty today before Senior U.S. District Court Judge Robert E. Blackburn to charges related to the illegal dispensing and distribution of controlled substances, U.S. Attorney Bob Troyer and DEA Denver Division Special Agent in Charge Tim McDermott announced. Both defendants are scheduled to be sentenced by Judge Blackburn on March 14, 2019.

According to the stipulated facts contained in both defendants’ plea agreements, Stanley Callas and Scott Eskanos were co-owners of Crown Point Pharmacy, located in Parker, Colorado, and Sky Ridge Pharmacy, located at in Lone Tree, Colorado. Callas typically dispensed controlled substances from Crown Point Pharmacy and Eskanos typically dispensed controlled substances from Sky Ridge Pharmacy.

Callas pled guilty to illegal distribution of controlled substances on Sept. 13, 2012, when he dispensed morphine, meperidine, and lorazepam to co-defendant Dianna Smithling outside the usual course of professional practice and for a purpose other than a legitimate medical purpose. Specifically, on Sept. 13, 2012, Callas filled prescriptions for 1,500 morphine sulfate IR 30mg tablets; 450 morphine sulfate ER 60mg tablets; 30 morphine sulfate 100mg tablets; 180 injectable meperidine 100mg/ml vials; and 270 lorazepam 2mg tablets. Each prescription was written by co-defendant Dr. John Alan Littleford and purported to be for a 90-day supply. Smithling was Dr. Littleford’s office manager at the Pain & Injury Clinic in Parker, Colorado, when Callas distributed the controlled substances to her.

Based on the numbers of dosage units, the morphine equivalencies, plus the synergistic effects of taking these controlled substances together, Callas knew or should have known these prescriptions were not for a legitimate medical purpose. Callas also filled additional prescriptions well before the prescriptions he filled on Sept. 13, 2012, were scheduled to run out. On Oct. 9, 2012—approximately 26 days into the 90-day supply filled on September 13—Callas filled another prescription for 180 injectable meperidine 100mg/ml vials which was supposed to last for another 90 days. On Nov. 5, 2012—approximately 53 days into the 90-day supply filled on September 13—Callas filled a prescription for 400 more morphine sulfate 30mg tablets and a prescription for 180 morphine sulfate 200mg tablets. Crown Point Pharmacy maintained real-time computer data which was accessible to Callas at every dispensing and made him aware of Crown Point Pharmacy’s dispensing history for each individual to whom he dispensed controlled substances. Callas did not exercise the degree of independent judgment which was required of him by law.

As part of his plea agreement, Callas agrees the Court can consider his distribution of controlled substances on five other occasions—involving more than 3,600 pills of various opioids, amphetamines, and benzodiazepines as well as fentanyl patches and vials of injectable meperidine—as relevant for sentencing in his case.

Eskanos pled guilty to illegal distribution of controlled substances on Sept. 12, 2012, when he dispensed 840 oxycodone 30mg tablets to an individual who presented a prescription written by co-defendant Dr. Littleford outside the usual course of professional practice and for a purpose other than a legitimate medical purpose. Based on the numbers of dosage units and the morphine equivalencies, Eskanos knew or should have known this prescription was not for a legitimate medical purpose. Eskanos deliberately ignored obvious red flags in order to fill illegitimate prescriptions which were presented and which bore Dr. Littleford’s signature. For example, a review of historical data through the Colorado Prescription Drug Monitoring Program or additional investigation with Dr. Littleford’s office would have revealed Dr. Littleford was also writing monthly prescriptions for the same individual for 360 oxycodone/acetaminophen 10mg/325mg tablets; 120 oxycodone 80mg tablets; 240 morphine sulfate ER 100mg tablets; 240 clonazepam 2 mg tablets; and 60 temazepam 15mg tablets, which the individual was filling at a pharmacy called Dale’s Pharmacy. In total, the individual was receiving 1,320 pills of oxycodone per month in addition to morphine and benzodiazepines. Sky Ridge Pharmacy maintained real-time computer data which was accessible to Eskanos at every dispensing and made him aware of Sky Ridge Pharmacy’s dispensing history for each individual to whom he dispensed controlled substances. Eskanos did not exercise the degree of independent judgment which was required of him by law.

As part of his plea agreement, Eskanos agrees the Court can consider his distribution of controlled substances on three other occasions—involving 1,500 pills of oxycodone and diazepam—as relevant for sentencing in his case.

As a term of their pretrial release in April 2016, Callas and Eskanos both agreed they would not be employed in any pharmaceutical capacity. Through their plea agreements, both defendants now agree they will not seek new pharmacy licenses or the return of the pharmacy licenses they previously surrendered pursuant to Non-disciplinary Cessation of Practice Agreements they reached with the Colorado Board of Pharmacy on April 22, 2016.

This case was investigated by the DEA Denver Division.

The defendants are being prosecuted by Assistant U.S. Attorneys  Peter McNeilly and Jaime Pena.

  • Facebook
  • Twitter
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Quienes Somos
    • Sobre
    • Divisiones Nacionales
    • Oficinas Extranjeras
    • Contáctenos
    • Museo DEA
  • Lo Que Hacemos
    • Prevención de Drogas
    • Aplicacion de la Ley
    • División de Control de Desvío
    • Noticias
  • Carreras
    • Resumen
    • Agente Especial
    • Investigador de Desvío
    • Especialista en Investigación de Inteligencia
  • Recursos
    • Información sobre las Drogas
    • Programa de Asistencia al Empleado
    • Empleador con Igualdad de Oportunidades
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Hacer Negocios
    con la DEA
    • Resumen
    • Proveedores Actuales
    • Futuros Vendedores
    • Cláusulas de Seguridad
    • Formularios de Seguridad
    • Programa de Pequeñas Empresas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
Inicio

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster